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Abstract
Background: Pancreatic adenocarcinoma is a highly invasive neoplasm. Epidermal growth factor
(EGF) and its receptor are over expressed in pancreatic cancer, and expression correlates with
invasion and metastasis. We hypothesized that EGF receptor and integrin signalling pathways
interact in mediating cellular adhesion and invasion in pancreatic cancer, and that invasiveness
correlates temporally with detachment from extracellular matrix.
Methods: We tested this hypothesis by investigating the role of EGF in mediating adhesion to and
invasion through collagen I and Matrigel in the metastatic pancreatic adenocarcinoma cell line
Capan-1. Adhesion and invasion were measured using in vitro assays of fluorescently-labeled cells.
Adhesion and invasion assays were also performed in the primary pancreatic adenocarcinoma cell
line MIA PaCa-2.
Results: EGF inhibited adhesion to collagen I and Matrigel in Capan-1 cells. The loss of adhesion
was reversed by AG825, an inhibitor of erbB2 receptor signalling and by wortmannin, a PI3K
inhibitor, but not by the protein synthesis inhibitor cycloheximide. EGF stimulated invasion through
collagen I and Matrigel at concentrations and time courses similar to those mediating detachment
from these extracellular matrix components. Adhesion to collagen I was different in MIA PaCa-2
cells, with no significant change elicited following EGF treatment, whereas treatment with the EGF
family member heregulin-alpha elicited a marked increase in adhesion. Invasion through Matrigel in
response to EGF, however, was similar to that observed in Capan-1 cells.
Conclusion: An inverse relationship exists between adhesion and invasion capabilities in Capan-1
cells but not in MIA PaCa-2 cells. EGF receptor signalling involving the erbB2 and PI3K pathways
plays a role in mediating these events in Capan-1 cells.
Background
Pancreatic cancer carries a poor prognosis due to the
advanced level of tumor invasion and metastasis often
encountered at the time of diagnosis [1]. A clear under-
standing of the cellular processes involved in pancreatic
cancer invasiveness and metastasis may be useful in the
development of novel forms of therapy. The receptor tyro-
sine kinase epidermal growth factor receptor (EGF-R) and
its ligands are over expressed in pancreatic cancer tissues
and in pancreatic cancer cell lines [2,3], with coexpression
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of receptor and ligand correlating with tumor invasiveness
[4]. The mitogenic effects of EGF-R stimulation in pancre-
atic cancer are well established [5,6]. The importance of
EGF-R signalling in promoting and maintaining pancre-
atic cancer growth is highlighted by studies showing
decreased growth in mice treated with a receptor tyrosine
kinase blocker [7] and by an EGF-R blocking antibody
[8,9].
In contrast to the role of EGF-R and its ligands on cell pro-
liferation, the mechanisms involved in EGF-R mediated
invasiveness in pancreatic cancer cells are unclear. Specif-
ically, the role of EGF-R signalling with respect to cellular
adhesion to extracellular matrix, cellular motility and
invasion through extracellular matrix in pancreatic cancer
cells are not known. The involvement of EGF-R and
related erbB receptor tyrosine kinases in cancer cell inva-
sion is suggested by studies in colon and mammary carci-
noma cell lines. In colon cancer cells, EGF-R activation
correlates with the development of liver metastases
[10,11]. In breast cancer cells, heregulin-alpha (HRG-α ),
an EGF family member that binds to erbB3 and erbB4 and
facilitates heterodimerization of these receptors with the
erbB2 receptor, regulates the actin cytoskeleton and pro-
motes invasion [12]. Signalling via the erbB family of
receptor tyrosine kinases therefore is likely to play an
important role in mediating pancreatic cancer invasive-
ness as well.
A combination of signals from cytokine, growth factor
and adhesion receptors regulates cell motility. In cancer
cells, motility may become dysregulated leading to
increased invasive potential. A model of cancer cell inva-
sion would include the loosening of attachment to the
primary tumor mass in a process involving detachment
from extracellular matrix. The detached cells would then
penetrate the extracellular matrix thereby leading to cell
migration and invasion. Because EGF and related erbB
receptor ligands have been implicated in cellular adhesion
and migration [13-17], we set out to investigate the role of
EGF in adhesion and invasion in a pancreatic cancer cell
line. We chose Capan-1 cells, as these are well-differenti-
ated cells originally isolated from liver metastases in a
patient with pancreatic cancer [18]. We also performed
adhesion and invasion studies on MIA PaCa-2 cells,
which were originally isolated from a primary pancreatic
adenocarcinoma, to determine whether adhesion and
invasion characteristics were shared between these cells
and Capan-1 cells.
Methods
Materials
Eagle's minimum essential media (EMEM), FBS, trypsin-
EDTA, penicillin-streptomycin, phalloidin-TRITC,
fibronectin, collagen I, laminin IV, AG825, wortmannin
and Cell Dissociation Solution were from Sigma (St.
Louis, MO). RPMI 1640 media was from GIBCO BRL
(Grand Island, NY). Matrigel was from Becton Dickenson
Biosciences (Bedford, MA). Recombinant human EGF was
from Calbiochem (San Diego, CA). Recombinant heregu-
lin-α  was from R&D Systems (Minneapolis, MN). Vitro-
gen was from Celtrix (Palo Alto, CA). Transwell cell
culture plates (diameter 24 mm; pore size 3.0 µm) were
from Costar (Cambridge, MA). Six well and 96 well plates
were from Becton Dickinson (Franklin Lakes, NJ).
Enhanced chemiluminescence detection reagents (ECL-
Plus) were from Amersham Pharmacia (Piscataway, NJ).
Calcein-AM, To-Pro-3 iodide and fluorescein-conjugated
goat anti-rabbit IgG were from Molecular Probes (Eugene,
OR). The anti-human mouse monoclonal EGF-R and the
anti-human rabbit polyclonal EGF antibodies was from
Oncogene (Boston, MA). Anti-human mouse monoclonal
erbB2 and erbB3 antibodies were from NeoMarkers (Fre-
mont, CA). For western blotting, α 2 integrin and β 1
integrin anti-human mouse monoclonal antibodies were
from Transduction Laboratories (Lexington, KY). The rab-
bit anti-human GAPDH antibody was from Novus (Little-
ton, CO). The human EGF ELISA kit was from Biomedical
Technologies (Stoughton, MA).
Cell lines and cell culture
Capan-1 cells were obtained from American Type Culture
Collection (Manassas, VA) and cultured in RPMI 1640
supplemented with 15% FBS and 2 mM L-glutamine. MIA
PaCa-2 cells were also obtained from American Type Cul-
ture Collection and cultured in Dulbecco's modified Eagle
medium supplemented with 10% FBS and 4 mM L-
glutamine. Cells were passaged when confluent. Once
confluent, cells were switched over to serum free media
gradually over three successive feedings on alternate days,
then treated with growth factors in serum free media for
the indicated time periods. Human fibroblasts were
derived from human gallbladders and cultured on six-well
plates as previously described [19].
Adhesion assay
Adhesion assays were conducted in 96 well plates coated
overnight at 4°C with 10 µg/ml collagen I, Matrigel, lam-
inin IV, fibronectin, hyaluronic acid or 1% BSA. After
coating, the wells were incubated with 1% BSA in PBS for
1 hour at 37°C, then washed with PBS before use. Cells
were labelled for 1 hour with 1 mM Calcein AM at 37°C,
washed with PBS, and then detached with 5 mM EDTA in
PBS or with Cell Dissociation Solution. Detached cells
were washed once more in PBS, resuspended in serum free
media and added to the wells (5 × 104 cells per well). The
plates were then incubated at 37°C for 1 hour. Each well
was then washed three times in PBS, and then overlaid
with serum free media prior to quantification. The per-
centage of adherent cells was determined using aBMC Gastroenterology 2005, 5:12 http://www.biomedcentral.com/1471-230X/5/12
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Cytofluor 4000 fluorescence plate reader (Applied Biosys-
tems, Foster City, CA), with excitation wavelength 485 nm
and emission wavelength 530 nm. Results are expressed as
the ratio of fluorescence from wells containing matrix to
uncoated control wells containing 5 × 104 cells.
For the adhesion assays using inhibitors, growth factor
treatment duration was 8 hours. Cells were also treated
with the indicated inhibitors at the following final con-
centrations and durations of preincubation prior to addi-
tion of growth factor: cycloheximide 10 µM for 30
minutes; wortmannin 100 nM in DMSO for 60 minutes;
AG825 25 µM in DMSO for 60 minutes; erbB2 and erbB3
blocking antibodies 10 µg/ml for 30 minutes. Initial
experiments were performed with a range of doses, with
the indicated doses being the ones for which data are
shown. Inhibitors were present throughout the duration
of exposure to growth factor or vehicle. Cell toxicity was
monitored using trypan blue exclusion during incuba-
tions with inhibitors, with no treatment leading to >5%
cell death.
Invasion assay
Invasion assays were performed using a modification of a
previously described method [20]. Briefly, 8 µM pore HTS
Fluoroblok filters (Becton Dickenson) were coated over-
night with 300 µl Matrigel or collagen I diluted to 100 µg/
ml in PBS at 4°C. The matrix was rehydrated for two hours
with serum free media prior to use, then washed once
with PBS. Cells were labelled for 1 hour with 1 mM Cal-
cein AM at 37°C, washed with PBS, and then detached
with 5 mM EDTA in PBS or with Cell Dissociation Solu-
tion. Detached cells were washed once more in PBS, resus-
pended in serum free media and added to the invasion
chamber (1 × 105 cells per well). The chambers were incu-
bated at 37°C for up to 48 hours. The percent of cells
invading to the bottom of the membrane was then quan-
tified using a Cytofluor 4000 fluorescence plate reader.
Results are expressed as the ratio of fluorescence from cells
invading to control wells containing 1 × 105 cells.
Confocal laser scanning immunofluorescence microscopy
Cells were cultured in 24 mm diameter Transwell inserts
until confluent. Cells were washed twice with ice cold
PBS, then a square of membrane was excised. This square
was then fixed in methanol/acetone (1:1; v/v) for 15 min-
utes at -20°C. The fixed cells were then washed in ice cold
PBS and incubated for 30 minutes in the presence of PBS
containing 1% BSA. The cells were then washed in PBS
and incubated in primary antibody diluted in PBS con-
taining 1% BSA. After one hour, the cells were again
washed and incubated with secondary antibody in PBS
containing 1% BSA. The secondary antibody was removed
after one hour by washing with PBS. To-Pro-3 iodide was
applied for 1 hour. Cells were washed three times with
PBS and sealed in Vectashield Hard Set mounting
medium (Vector Labs, Burlingame, CA). Scanned images
were acquired with 400× optical and 3× digital magnifica-
tion using a laser scanning spectral confocal microscope
system (Leica DM-R upright fluorescence microscope and
Leica TCS-SP confocal scanner). Single serial section
images in the xy plane were acquired. Cells treated with
secondary antibody only did not show detectable signals
at the parameters used for acquiring images.
Immunoblotting
Cells were cultured to confluency on six well plates and
harvested with SDS loading buffer (250 mM Tris, ph 6.8;
4% SDS; 10% glycerol; 0.006% bromphenol blue; and
2% β -mercaptoethanol). Protein content of cell extracts
was measured by the Lowry method. SDS-PAGE was per-
formed followed by transfer to PVDF membrane. The
membranes were blocked with 10% BSA in PBS/Tween 20
(0.05%; v/v) at 4°C for 16 hours and then incubated with
the anti-α 2 integrin or β 1 integrin antibodies for 1 hour at
room temperature. The membrane was then washed with
0.05% Tween 20 in PBS and incubated with peroxidase-
conjugated anti-mouse IgG antibody for 1 hour at room
temperature. The membrane was washed and incubated
with ECL-Plus and autoradiography performed. We also
ran blots in parallel that were hybridized with rabbit anti-
human GAPDH antibody to confirm equal protein
loading.
ELISA assay
Capan-1 cells and human gallbladder myofibroblasts
were cultured until confluent in 6 well plates. Upon
achieving confluency, cells were then cultured in media
containing 10% FBS or in serum free media. Following 48
hours of incubation, media was collected, centrifuged to
pellet cell debris and floating cells, and soluble EGF levels
quantitated using a human EGF ELISA kit, using 96 well
plates and a microplate fluorescence reader per the manu-
facturer's instructions. The sensitivity of this method was
to 0.5 ng/ml soluble EGF.
Statistical analysis
A minimum of three separate experiments (with each
treatment condition performed in triplicate) was per-
formed for the adhesion and invasion assays. Results of
experiments are expressed as the mean percentage ± SD of
cells that are adherent or invading compared to cells from
control wells. Student's t test was used, and p < 0.05 was
considered significant.
Results
Capan-1 adhesion to collagen I is inhibited by EGF
We first examined the ability of Capan-1 cells to adhere to
various extracellular matrix components. As shown in Fig-
ure 1, Capan-1 cells adhered to a variety of matrices,BMC Gastroenterology 2005, 5:12 http://www.biomedcentral.com/1471-230X/5/12
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including laminin IV, fibronectin, collagen I and Matrigel.
Capan-1 cells did not adhere to any significant degree to
hyaluronic acid or to BSA.
We then determined the effects of EGF on adhesion to
these extracellular matrix components. For this set of
experiments, EGF treatment was provided for 8 hours
prior to the initiation of the adhesion assay. Adhesion to
collagen I decreased upon treatment with EGF. Similarly,
adhesion to Matrigel decreased with EGF treatment. In
contrast, treatment with EGF increased adhesion to
fibronectin. There was no difference in adhesion to lam-
inin IV. Finally, even though adhesion to hyaluronic acid
was low at baseline, EGF treatment increased adhesion.
No significant change in adhesion was noted on BSA with
EGF treatment. EGF therefore has varied effects on adhe-
sion to various extracellular matrix components, mediat-
ing detachment from collagen I and Matrigel, while
potentiating adhesion to fibronectin and hyaluronic acid.
Heregulin-α  (HRG-α ) belongs to the same family as EGF,
binds to erbB3 and erbB4 receptors and is capable of het-
erodimerization with the erbB2 receptor in other cell
types [12]. We therefore used HRG-α  as an indirect means
to determine whether the EGF-mediated effects on adhe-
sion were shared by activation of erbB3 and erbB4 recep-
tors. We tested the effects of HRG-α  on the adhesion of
Capan-1 cells to the same set of extracellular matrix com-
ponents and for the same duration of treatment. In con-
trast to the results with EGF, there was no significant
inhibition of adhesion to collagen I with HRG-α  treat-
ment. In addition, HRG-α  did not alter adhesion to
laminin IV, fibronectin, hyaluronic acid or BSA. There was
a significant decrease in adhesion to Matrigel (from 57.95
% ± 2.5 to 33.6 % ± 2.9; p = 0.003) with HRG-α  treatment.
These results imply that the inhibition of adhesion to col-
lagen I occurred without involvement of erbB3 or erbB4
receptors. The inhibition of adhesion to Matrigel, how-
ever, appeared to involve receptors activated by either EGF
or HRG-α .
Adhesion of cells to various extracellular matrix components and the effect of EGF Figure 1
Adhesion of cells to various extracellular matrix components and the effect of EGF. Adhesion was tested under 
conditions of no growth factor (open symbols) and treatment with 10 nM EGF (closed symbols) for 8 hours. Results are 
expressed as % adhesion ± SEM from three separate experiments, each performed in triplicate wells. * p < 0.003; ** p < 0.05.
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Evidence that the EGF-mediated detachment from 
collagen I in Capan-1 cells involves erbB1 and erbB2 
receptors and the phosphatidylinositol-3 kinase signalling 
pathway
We focused on adhesion to collagen I by Capan-1 cells
given the marked inhibition of adhesion seen with EGF.
In order to begin to delineate the pathways involved in
this detachment, we examined the effect of various inhib-
itors: cycloheximide, a protein synthesis inhibitor; wort-
mannin, an inhibitor of phosphatidylinositol-3 kinase;
AG825, a pharmacologic inhibitor of the erbB2 receptor;
a blocking antibody against the erbB2 receptor; and a
blocking antibody against the erbB3 receptor. Each of
these inhibitors did not alter adhesion to collagen I to any
significant degree in the absence of growth factor treat-
ment (Figure 2). EGF-mediated de-adhesion to collagen I
was not reversed by cycloheximide, suggesting that new
protein synthesis was not involved. Similarly, treatment
with a blocking antibody against the erbB3 receptor did
not alter this EGF-mediated detachment. On the other
hand, treatment with wortmannin reversed the EGF-
mediated detachment, implying a phosphatidylinositol-3
kinase mediated pathway was involved (EGF = 30.5 % ±
2.1 vs. EGF + wortmannin = 50.5 % ± 3.8; p < 0.001; n =
10). Similarly, an inhibitor of the erbB2 receptor, AG825
and a blocking antibody against erbB2 reversed the EGF-
mediated detachment (to 49.9 % ± 1.7; p = <0.001; n = 10;
and to 48.6 % ± 2.4; = <0.001; n = 5, respectively). The
similar magnitude of this inhibition of the EGF-induced
detachment suggested that the erbB2 receptor signalling
pathway and the phosphatidylinositol-3 kinase pathway
were involved simultaneously.
We also examined the effects of this panel of inhibitors on
cells adhering to collagen I and treated with HRG-α . There
was no effect on adhesion to collagen I with HRG-α  treat-
ment, a finding that was not altered with treatment with
wortmannin or the erbB2 receptor inhibitor AG825 (Fig-
ure 2). Furthermore, blocking antibodies against the
erbB2 and erbB3 receptors did not alter this lack of effect
Effects of various inhibitors on adhesion of cells to collagen I Figure 2
Effects of various inhibitors on adhesion of cells to collagen I. Adhesion assays on collagen I were performed with no 
growth factor (open bars), 10 nM EGF (closed bars) or 10 nM HRG-α  (hatched bars). Shown are the results of three separate 
experiments, each performed in triplicate. * p < 0.001. **p < 0.02.BMC Gastroenterology 2005, 5:12 http://www.biomedcentral.com/1471-230X/5/12
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of HRG-α  on adhesion to collagen I (data not shown).
Cycloheximide decreased adhesion in the presence of
HRG-α , (from 57.0 % ± 1.6 to 50.4 % ± 2.1; p = 0.02; n =
10), suggesting that protein synthesis was involved to a
limited degree in maintaining adhesion to collagen I with
HRG-α  treatment. Overall, these results suggested that the
detachment from collagen I was an EGF-specific effect,
which was not shared by the related growth factor, HRG-
α . This de-adhesive effect is therefore likely mediated
through activation of the EGF-R and partially through
activation of the erbB2 receptor, and involves the phos-
phatidylinositol-3 kinase signalling pathway.
Lack of a de-adhesion response to Collagen I of EGF in a 
primary pancreatic cancer cell line (MIA PaCa-2)
MIA PaCa-2 cells are derived from a primary, non-meta-
static pancreatic adenocarcinoma, unlike Capan-1 cells,
which were isolated from liver metastases. We therefore
asked whether the adhesion response to EGF on collagen
I was a property shared between these two pancreatic can-
cer cell lines. Adhesion to collagen I was markedly dimin-
ished in MIA PaCa-2 cells under control conditions
compared to Capan-1 cells. Treatment with EGF (10 nM
for 8 hours) did not show a significant change in adhe-
sion. Strikingly, however, treatment with HRG-α  showed
a marked increase in adhesion to collagen I (Figure 3).
This effect of HRG-α  was abrogated by pre-treatment with
either cycloheximide or the erbB-2 inhibitor, AG825, sug-
gesting that protein synthesis and activation of the erbB-2
receptor were involved in the HRG-α  response. HRG-α ,
and by implication, activation of the erbB3 and/or erbB4
receptors in concert with erbB-2 receptor activation,
appears to mediate adhesion to collagen I in this cell line.
EGF stimulates invasion through collagen I and Matrigel in 
Capan-1 cells
We next examined the effects of EGF on invasion through
collagen I and Matrigel. We chose collagen I because of
the clear detachment response to EGF noted above. We
also chose to examine invasion through Matrigel, as this is
a more complex matrix that simulates extracellular matrix
in vivo and serves as a more physiologic substrate on
which to measure invasion capabilities of Capan-1 cells.
Furthermore, the studies on adhesion had shown parallel
effects with EGF treatment, suggesting that collagen I and
Matrigel possessed similar properties with respect to adhe-
sion and invasion. Capan-1 cells showed an increase in
invasion following addition of EGF which was seen with
both collagen I (data not shown) and with Matrigel (Fig-
ure 4). No effect on invasion through either collagen I or
Matrigel was seen with HRG-α .
Effects of cycloheximide and AG825 on adhesion of MIA  PaCa-2 cells to collagen I Figure 3
Effects of cycloheximide and AG825 on adhesion of 
MIA PaCa-2 cells to collagen I. Adhesion assays on colla-
gen I using were performed with no growth factor (open 
bars), 10 nM EGF (closed bars) or 10 nM HRG-α  (hatched 
bars). Shown are the results of three separate experiments, 
each performed in triplicate. * p < 0.001.
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Effects of EGF and HRG-α  on invasion through Matrigel in  Capan-1 and MIA PaCa-2 cells Figure 4
Effects of EGF and HRG-α  on invasion through 
Matrigel in Capan-1 and MIA PaCa-2 cells. Cells were 
cultured on invasion chambers coated with Matrigel, and 
invasion measured following treatment with no growth fac-
tor, 10 nM EGF, or 10 nM HRG-α . Shown are the results of 
3 experiments, each performed in triplicate wells. *p < 0.05 
between the no growth factor group and the EGF treatment 
group for each cell type.
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EGF stimulates invasion through Matrigel in MIA PaCa-2 
cells
We also assessed invasion through Matrigel with and
without growth factor treatment on MIA PaCa-2 cells. As
shown in Figure 4, EGF treatment enhanced invasion to a
similar extent as in Capan-1 cells, whereas HRG-α  had no
effect. Therefore, the de-adhesive response to EGF is
absent in the MIA PaCa-2 cells, whereas the invasive
response to Matrigel is preserved.
Time course of EGF-mediated inhibition of adhesion and 
stimulation of invasion
Given the EGF-mediated effects on both adhesion and
invasion, which were not seen with HRG-α , erbB1/erbB2
receptor signalling pathways were likely involved in medi-
ating both detachment from extracellular matrix and the
stimulation of invasion noted in Capan-1 cells. We
explored the effects of EGF signal duration on detachment
and invasion in Capan-1 cells. EGF treatment led to a
time-dependent detachment from collagen I, which was
slowly reversible (Figure 5). The peak inhibition of adhe-
sion occurred with 8 hours of EGF treatment.
The time course of invasion through Matrigel showed that
the EGF-mediated increase in invasion peaked at 24 hours
of treatment, and then began to slowly return to pre-treat-
ment levels (Figure 6). Therefore, the EGF-mediated inhi-
bition of adhesion was followed by an EGF-mediated
increase in invasion, suggesting a temporal relationship
between loss of attachment to extracellular matrix and
acquisition of the ability to invade.
Dose response of EGF-induced detachment from collagen 
I and invasion through Matrigel
This temporal relationship was supported by the finding
that the EGF dose response for both adhesion and inva-
sion were similar (Figure 7). Concentrations greater than
0.01 nM were required to see effects on both of these phe-
nomena. For these studies, the duration of treatment with
EGF was held constant at 24 hours, a time when both
detachment and invasion were statistically significantly
different between treated and non-treated cells. The dose
Time course of EGF-mediated inhibition of adhesion Figure 5
Time course of EGF-mediated inhibition of adhesion. 
The adhesion assay was performed and the experiment ter-
minated at various time points. Adhesion was measured 
without and with EGF treatment. Shown are the results of 
one experiment performed in triplicate wells, which was 
repeated twice with similar results.
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The time course of EGF-mediated invasion through Matrigel Figure 6
The time course of EGF-mediated invasion through 
Matrigel. Cells were labeled and invasion through chambers 
performed in the absence or presence of 10 nM EGF. Shown 
are the results of one experiment performed in triplicate 
wells, which was repeated twice with similar results.
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of EGF chosen for the earlier assays on adhesion and inva-
sion (10 nM) was justified by these dose response studies,
as at that concentration a plateau of both detachment and
invasion were seen.
Expression of EGF receptor, α 2 integrin and β 1 integrin in 
Capan-1 cells
EGF effects are mediated predominantly through the EGF
receptor (EGF-R). EGF-R expression was demonstrated in
Capan-1 cells by confocal immunofluorescence micros-
copy (Figure 8A). As effects of adhesion and invasion were
likely to involve integrins, we sought to demonstrate
expression of the integrins involved in adherence to colla-
gen I, the α 2 and β 1 integrins. As shown in Figure 8B, α 2
integrin was expressed on the cell surface of Capan-1 cells.
Similarly, the β 1 integrin was expressed on the surface of
Capan-1 cells (Figure 8C). These results demonstrate that
the EGF-mediated effects of adhesion and invasion in
Capan-1 cells were likely to involve the EGF receptor, as
well as the collagen I receptor, the α 2β 1  integrin
heterodimer.
We next asked whether α 2/β 1 integrin expression levels
were affected by EGF treatment. No significant difference
in signal for either α 2 integrin or for β 1 integrin was noted,
either by immunofluorescence or immunoblot analysis,
following treatment with 10 nM EGF (data not shown).
Dose response of EGF-induced detachment from collagen I  and stimulation of invasion through Matrigel Figure 7
Dose response of EGF-induced detachment from col-
lagen I and stimulation of invasion through Matrigel. 
Adhesion and invasion were measured following incubation 
with escalating doses of EGF. Shown are the results of three 
experiments, each performed in triplicate.
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Expression of EGFR, α 2/β 1 integrin in Capan-1 cells Figure 8
Expression of EGFR, α 2/β 1 integrin in Capan-1 cells. Cells were cultured on Transwell inserts, and confocal immunoflu-
orescence microscopy performed following incubation with primary antibodies against EGF-R (A), α 2 integrin (B) and β 1 
integrin (C). Negative controls with primary antibody omitted did not show a detectable signal.
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EGF treatment induces rearrangements in the actin 
cytoskeleton
ErbB1/erbB2 receptor tyrosine kinase signalling mediated
by EGF binding has been linked to integrin expression via
effects on the focal adhesion complex [21]. One impor-
tant downstream effect of changes in the focal adhesion
complex is actin cytoskeleton rearrangement. Therefore,
we looked for changes in actin cytoskeleton architecture
using phalloidin staining in cells treated with EGF. As
shown in Figure 9, phalloidin staining showed focal areas
of staining suggestive of focal adhesion complexes in cells
treated with EGF compared to untreated cells.
Expression of EGF in Capan-1 cells does not correlate with 
EGF secretion
In vivo, the source of EGF that drives a cancer cell to
become invasive may be adjacent cancer cells, adjacent
mesenchymal cells, or the cancer cell itself. In order to
determine the source of EGF involved in these EGF-medi-
ated effects on adhesion and invasion in Capan-1 cells, we
looked for evidence of endogenous EGF synthesis and
secretion. An ELISA for human EGF showed no soluble
EGF secreted by Capan-1 cells, whereas cultured human
myofibroblasts secreted soluble EGF, consistent with pre-
vious reports (Figure 10A) [22]. On immunofluorescence
microscopy with an EGF antibody, however, EGF was
expressed on the plasma membrane of Capan-1 cells
(Figure 10B). These results suggest that Capan-1 cells syn-
thesize but do not secrete EGF.
Discussion
Drugs that target the EGF receptor offer promise for more
effective treatment of pancreatic cancer [1]. For example,
Gefitinib, a selective EGF receptor tyrosine kinase
inhibitor, inhibits pancreatic cancer cell growth and inva-
sion [23]. Understanding the mechanisms of EGF-
induced cellular invasion in pancreatic cancer cells there-
fore is critical, as such insights could provide a means to
define subpopulations of tumors more likely to be
responsive to these agents and allow for more focused tar-
geting strategies in future drug design [24]. In the current
work, we have provided data to support a model in which
EGF-mediated effects on de-adhesion and invasion occur
via the EGF-R and erbB-2 receptor involving the PI3
kinase signalling pathway in Capan-1 cells. The involve-
ment of the PI3-kinase pathway has also been reported in
glial cell line-derived neurotrophic factor-induced migra-
tion and invasion in pancreatic cancer cells, suggesting
that this signalling mechanism may be common to the
invasion phenotype in pancreatic cancer cells [25]. Fur-
thermore, we provide evidence that EGF-mediated de-
adhesion and invasion are temporally linked phenomena,
occurring in cells that are capable of synthesizing both
EGF and EGF-R. The lack of EGF secretion by these cells
Phalloidin-TRITC staining of cells with and without EGF treatment Figure 9
Phalloidin-TRITC staining of cells with and without EGF treatment. Cells were cultured on Transwell inserts, and 
confocal immunofluorescence microscopy performed following incubation with TRITC-conjugated phalloidin, in the absence 
(A) or presence (B) of 10 nM EGF. Arrow shows focal area of actin staining consistent with a focal adhesion complex.
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suggests that the drive to invasiveness in these cells may be
provided by cell-cell interactions that promote EGF-R acti-
vation, although alternative mechanisms involving EGF
have not been ruled out by our results.
It is interesting to compare and contrast the results
obtained by Stefani et al with our data, because these
investigators used the same pancreatic cancer cell lines
(Capan-1 and MIA PaCa-2), and assessed the response to
Soluble EGF levels in incubation media from Capan-1 cells compared to media from human gallbladder myofibroblasts Figure 10
Soluble EGF levels in incubation media from Capan-1 cells compared to media from human gallbladder myofi-
broblasts. Cells were cultured in media with or without 10% FBS. Shown are the results of one experiment, which was 
repeated with similar results (A). B. Confocal immunofluorescence image of confluent Capan-1 cells stained for EGF.
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EGF on adhesion on the same ECM components as in our
study [26]. In our study, EGF-mediated de-adhesion in
Capan-1 cells occurred with collagen I and Matrigel, and
not with other extracellular matrix components. This find-
ing is similar to results reported by Stefani et al in Capan-
1 cells, although in that study, the de-adhesion response
to EGF in Capan-1 cells did not reach statistical signifi-
cance and no further studies involving the mechanism
involved in this response were conducted. One important
difference between the methodologies used in these stud-
ies was in the time course of the adhesion assay. Stefani et
al treated their cells with daily EGF treatments for 5–6
days prior to performance of the adhesion assay. In con-
trast, our studies were performed on a much shorter time
scale. Indeed, our results can be reconciled by examina-
tion of the time course results presented in Figure 5, which
shows that continuous exposure to EGF for more than 32
hours leads to an abrogation of the de-adhesive response.
Therefore, the de-adhesive response to EGF in Capan-1
cells reported at 6 days by Stefani et al may have been less
significant than our results because the effect of EGF was
more pronounced at earlier time points. A similar expla-
nation would account for the differences in adhesion to
collagen I measured with and without EGF treatment in
MIA PaCa-2 cells.
The α 2/β 1 integrin heterodimer is the collagen I receptor,
which is found in numerous tissues [27,28]. The adhesion
assay results with collagen I implicated the α 2/β 1 integrin
heterodimer, which are expressed in Capan-1 cells [29].
Higher expression of α 2  integrin in pancreatic cancer
tissue compared with normal pancreas has been reported
previously [30]. However, the lack of change in expression
of α 2/β 1 integrin with EGF treatment in Capan-1 cells sug-
gested that functional activation of these integrins were
more important than absolute expression levels in medi-
ating the effects of EGF on adhesion. This effect of EGF
differs from that described in human cutaneous squa-
mous carcinoma cells, in which treatment with this
growth factor induces expression of α 2/β 1 integrins and
enhances adhesion and migration on type I collagen [31].
Therefore, the lack of increase in expression of α 2/β 1
integrin, and the de-adhesion response, are features that
distinguish the EGF-induced adhesion effects in Capan-1
cells from that in squamous carcinoma cells.
The studies with phalloidin, showing changes in localiza-
tion of actin microfilaments upon EGF exposure, impli-
cate a functional effect on focal adhesion complexes as
well. EGF receptor activation has been linked to focal
adhesion complex changes via activation of the focal
adhesion kinase, FAK [21]. As motility signalling derived
from EGF-R activation required FAK [21], the de-adhesion
and invasion responses noted in Capan-1 cells likely
involve FAK activation also. Further experiments are nec-
essary to prove that this link between EGF-R activation
and FAK activation leading to focal adhesion complex reg-
ulation and cell motility is in fact present in Capan-1 cells
as it is in other types of cancer cells [32-34].
The de-adhesive response was temporally and dose-
dependently linked to stimulation of invasion in Capan-1
cells, suggesting that these responses are linked. The
effects of EGF on invasion through collagen I and Matrigel
were also significant, and differed from HRG-α , which did
not display this effect. β 1 integrins have been implicated to
play a key role in pancreatic cancer cell invasion [35].
Furthermore, α 2 integrins have also been implicated in
EGF-induced invasion through collagen in keratinocytes
[36]. Taken within this context, the finding that EGF (but
not HRG-α ) induces invasion through collagen I and
Matrigel implicates the α 2/β 1 integrin in this response,
acting via EGF-R and erbB2 receptors. MIA PaCa-2 cells
share these properties with respect to invasion through
Matrigel. Metastatic dissemination mediated by increased
expression of α 2/β 1 integrin has been shown in ovarian
carcinoma cells, so integrin-mediated invasion capabili-
ties in Capan-1 and MIA PaCa-2 cells may also be opera-
tive [37]. In this respect, Capan-1 and MIA PaCa-2 cells
also differ from breast carcinoma cells, in which re-expres-
sion of α 2/β 1 integrins correlates with abrogation of the
malignant phenotype [38].
Recent reports have implicated the MUC4 mucin as an
intramembranous ligand for erbB2 [39]. Specifically, the
rat Muc4/Sialomucin complex interacts with erbB2 and
induces its autophosphorylation and translocation from
the basolateral to the apical membrane in CaCo-2 cells
[40]. Antisense plasmid-mediated down-regulation of
MUC4 expression in a pancreatic cancer cell line
enhanced adhesion and decreased motility, findings that
are consistent with our data [41]. While the pancreatic
cancer cell line used in that study was not Capan-1, and
while adhesion to and migration through plastic was
assessed, the fact that the general findings between the
report of Singh et al and our data are in agreement sug-
gests that erbB-2 signalling effects on adhesion and inva-
sion may not be limited to one particular pancreatic cell
line. In this context, the contrasting results on the collagen
I adhesion assay between Capan-1 cells and MIA PaCa-2
cells indicate that the de-adhesive response to EGF
appears to be a feature characteristic of a metastatic cell,
whereas stimulation of adhesion to collagen I by HRG-α
appears to be a feature of a primary pancreatic adenocar-
cinoma cell. Further experiments comparing these and
other pancreatic cancer cell lines would need to be per-
formed to determine whether these differential responses
to EGF and HRG-α  hold true.BMC Gastroenterology 2005, 5:12 http://www.biomedcentral.com/1471-230X/5/12
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Finally, the finding that Capan-1 cells expressed but did
not release EGF into the media has implications for the
self-sustaining stimulation of the EGF-R with respect to
invasion capabilities. Pancreatic cancer cells over express
EGF, along with other members of the EGF family such as
Cripto and epiregulin [42,43]. EGF-R, erbB-2 and related
members of the EGF receptor tyrosine kinases are also
over expressed in pancreatic cancer [44]. The co-expres-
sion of these EGF families of ligands and receptor tyrosine
kinases suggests that an autocrine mechanism is operative
in pancreatic cancer, thereby allowing autonomous acti-
vation of signalling pathways that manifests as an aggres-
sive tumor phenotype. [4,6]. Our data suggests that, at
least in Capan-1 cells, this autocrine mechanism may
need to be refined so that cell-cell interactions between
membrane-expressed but non-secreted EGF stimulates
EGF-R on adjacent cells. Pancreatic cancer cells destined
to invade extracellular matrix may therefore need to
perform this function in groups rather than as individual
cells.
Conclusion
In summary, our studies on Capan-1 cells have shown
that EGF-R and erbB2 receptor are likely involved in
mediating a temporally linked de-adhesive and invasion
response. These cellular functions involve the participa-
tion of α 2/β 1 integrins, which induce changes in the actin
cytoskeleton at points of contact with the extracellular
matrix. Finally, the autocrine nature of this growth factor
signalling likely involves cell-cell interactions as EGF is
synthesized but not secreted by these cells. These insights
refine our understanding of the complex cellular phenom-
ena that occur in vivo in the setting of pancreatic cancer
invasion and metastasis, and open up avenues for further
investigation into the mechanisms involved.
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